What was recalled
The U.S. Food and Drug Administration (FDA) has issued a recall involving a specific batch of prescription medication distributed by Apollo Care, LLC. This action centers on the product known as SEMAGLUTIDE 7.5mg (5mg/mL), which is formulated with Glycine 7.5 mg (5mg/mL). The medication comes in the form of a 1.5 mL sterile multi-dose vial. It is strictly designated for prescription use only and is intended exclusively for subcutaneous injection. This means it is designed to be injected into the fatty tissue just beneath the skin, rather than into a muscle or vein.
Apollo Care, LLC is the company responsible for this recall. Their business address is listed as 3801 Mojave Ct, Ste 102, Columbia, MO 65202. The specific item affected by this recall carries the National Drug Code (NDC) 71170-721-01. If you are checking your medication, it is crucial to look at the lot number printed on the packaging or vial. The recalled lot is identified as AC-017273. This particular batch has an expiration date of December 12, 2026, which indicates that the medication was still within its intended shelf life at the time of the recall announcement.
The recall was officially announced on July 29, 2026. At the time of this notice, the distribution pattern for the affected product covered the entire United States. This nationwide scope means that patients across all fifty states could potentially possess this specific lot of medication. The recall is classified as a Class II recall by the FDA. In regulatory terms, a Class II classification suggests that use of or exposure to the violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This classification helps prioritize the urgency and scope of the corrective actions required.
If you have been prescribed SEMAGLUTIDE by Apollo Care, LLC, your first step is to verify whether your specific vial matches the details provided above. Check the NDC number, the lot number (AC-017273), and the expiration date. Because the distribution was nationwide, there is no geographic limitation that would exclude you from being affected if you have this exact product. It is important to handle this information calmly but promptly, ensuring you can identify your medication correctly before taking any further action.
The hazard, explained
When you look at a sterile vial of medication like the Semaglutide product recalled by Apollo Care, LLC, you are expecting a perfectly clear solution. The FDA has classified this recall as Class II, which indicates a situation where use of or exposure to the defective product might cause temporary medical problems or serious health consequences that are not life-threatening. The core issue here is the presence of particulate matter—tiny solid particles floating within the liquid. In this specific case, the FDA identified these particles as nylon/polyamide and silk/proteinaceous-type materials. While "particulates" might sound like a minor quality control quirk, in the context of injectable drugs, it represents a significant breach of sterility and safety standards.
To understand why this is dangerous, we have to look at how these vials are manufactured and filled. The presence of nylon/polyamide suggests that microscopic fragments from manufacturing equipment or packaging components may have broken off during the filling process. Nylon is a synthetic polymer often used in filters, tubing, and seals within pharmaceutical production lines. If a seal degrades or a filter fails under pressure, tiny fibers can shed into the sterile solution. Similarly, silk/proteinaceous materials typically originate from biological sources or specific protein-based stabilizers used in drug formulation. When these substances are not fully dissolved or are introduced as foreign contaminants, they remain suspended in the fluid. Because the vial is labeled as "Sterile," users assume the contents are free from any unintended physical impurities.
The danger arises when that liquid is injected subcutaneously, meaning under the skin. Your body is designed to handle medications that are chemically compatible with your tissues, but it reacts strongly to foreign solids. When you inject particles of nylon or protein fragments, your immune system recognizes them as invaders. This can trigger a local inflammatory response at the injection site, leading to redness, swelling, pain, or even granulomas—small areas of inflammation that form when the body tries to wall off material it cannot digest or remove. In rare cases, if these particles are small enough to enter the bloodstream rather than staying in the subcutaneous tissue, they could travel to other parts of the body, potentially causing blockages in small blood vessels or triggering systemic allergic reactions.
Furthermore, particulate matter can compromise the chemical stability of the drug itself. Semaglutide is a complex peptide that requires precise pH and protein interactions to remain effective. Foreign particles can alter these interactions, potentially reducing the potency of the medication or causing it to degrade unpredictably. This means that even if you do not experience immediate physical irritation from the injection, you might not be receiving the correct therapeutic dose, which is critical for managing conditions like type 2 diabetes or obesity where consistent dosing is vital for long-term health outcomes.
Who is most at risk
To understand who is truly at risk in this specific recall, we first need to look closely at what the product actually is and how it is used. The item recalled by Apollo Care, LLC is Semaglutide 7.5mg (5mg/mL), a sterile multi-dose vial intended for subcutaneous injection. This is not an over-the-counter supplement or a topical cream; it is a prescription-only medication. Therefore, the primary group of people affected are those who have been prescribed this specific drug by a healthcare provider to manage conditions such as type 2 diabetes or weight management. If you do not have a prescription for Semaglutide, your personal risk from this specific batch is effectively zero, because you would not be administering it into your body.
Among those who have been prescribed this medication, the risk is not uniform. It stems directly from the identified hazard: the presence of particulate matter within the vial. The FDA has identified these particles as nylon/polyamide and silk/proteinaceous-type materials. When a patient injects this medication, they are pushing liquid through a needle into their fatty tissue. If that liquid contains visible or invisible foreign solids, those particles enter the bloodstream directly. This creates a unique danger profile for individuals who rely on frequent injections. Because this is a multi-dose vial, patients typically use it over a period of weeks or months. The risk is not just about one bad dose; it is about the potential for repeated exposure to these contaminants if the entire lot is compromised.
Certain physiological factors may make some patients more vulnerable to the consequences of particulate contamination than others. For instance, individuals with existing cardiovascular issues or compromised immune systems face higher stakes. Particulate matter in injections can potentially cause micro-emboli (tiny blockages) in small blood vessels or trigger inflammatory responses. While this is a general medical reality for any contaminated injection, those with weakened immune defenses—such as the elderly, patients undergoing chemotherapy, or individuals with chronic autoimmune conditions—may find it harder to fight off potential infections or inflammatory reactions that could arise from foreign material entering the body.
Additionally, anxiety and psychological stress play a significant role in who feels most at risk here. Semaglutide is often part of a long-term treatment plan for chronic conditions. Receiving news that your medication supply might be contaminated can cause significant distress. Patients who are already managing complex health routines may feel particularly vulnerable because they must suddenly navigate the uncertainty of whether their current vial is safe, how to dispose of it properly, and how to get a replacement without missing doses. This logistical gap in care can be risky for anyone dependent on consistent medication levels to keep their blood sugar or weight under control.
It is also important to note that while the recall is nationwide, the distribution pattern suggests that patients who purchased from specific distributors or pharmacies in Missouri or other affected regions might be disproportionately represented. However, because the NDC and lot number are the true identifiers, geography matters less than possession of Lot AC-017273. Ultimately, the people at greatest risk are those who currently possess this exact lot number, have not yet inspected their vials for clarity, and continue to use them without consulting their pharmacist or doctor first.
How to tell if you have the recalled item
Before taking any action or contacting a healthcare provider, it is essential to verify that you possess the specific product involved in this FDA recall. Because recalls often target precise batches rather than an entire brand line universally, checking your vial against the official details is critical. The recall involves Semaglutide 7.5mg (5mg/mL) and Glycine 7.5 mg (5mg/mL), supplied by Apollo Care, LLC. This product is a sterile, multi-dose vial intended for subcutaneous injection only. To confirm whether your medication is part of this recall, you need to examine the packaging and the vial label closely for several key identifiers.
First, look at the National Drug Code (NDC). The recalled items carry the specific NDC number 71170-721-01. This unique identifier is printed on the box and often on the vial label itself. If your vial has a different NDC, it was likely manufactured under a different batch or formulation and is not included in this specific recall notice. Next, you must check the lot number. The recall applies exclusively to lot number AC-017273. Lot numbers are typically printed on the side of the box or directly on the vial label. If your lot number does not match AC-017273 exactly, your product is safe from this particular issue.
Additionally, verify the expiration date. The recalled vials expire on 12/12/2026. While an expired drug should generally be discarded for safety and efficacy reasons, only those with the specific lot number and NDC combination are part of this regulatory action. The product is described as a 1.5 mL sterile multi-dose vial containing Semaglutide 7.5mg (5mg/mL) and Glycine 7.5 mg. Ensure the label clearly states "Rx Only" and indicates it is for subcutaneous injection. The manufacturer’s address, 3801 Mojave Ct, Ste 102, Columbia, MO 65202, may also appear on the packaging, confirming it originates from Apollo Care, LLC.
If you purchased this medication recently, recall that it was distributed nationwide within the United States. Therefore, location of purchase does not rule out the recall; even if you bought it in a different state, it could still be part of the affected batch. Do not rely solely on the appearance of the liquid or the color of the box, as these can vary by lighting or packaging design. Instead, stick to the hard data: NDC 71170-721-01, Lot AC-017273, and Exp. 12/12/2026. If any of these details do not match, you likely have a different product. When in doubt, take a photo of your vial’s label and consult your pharmacist or healthcare provider for confirmation before proceeding.
What to do — step by step
If you currently possess the recalled Apollo Care Semaglutide vials, your immediate priority is to ensure that you do not administer this medication to yourself or anyone else. The U.S. Food and Drug Administration has classified this recall as a Class II event, which indicates that use of the product may cause temporary health problems or pose a slight threat of a serious nature. Because the specific remedy details were not explicitly stated in the official FDA recall notice, you cannot rely on standard return instructions provided by the manufacturer for this specific lot. Instead, you must take proactive steps to secure your health and properly dispose of or handle the product under professional guidance. First, stop using the vial immediately. Do not attempt to filter the contents or clear the particulate matter yourself, as this can compromise the sterility of the remaining solution and introduce new contaminants. The identified particles, described as nylon/polyamide and silk/proteinaceous-type materials, are foreign substances that should never enter your bloodstream via subcutaneous injection. Even if the vial appears clear at first glance, microscopic particulates may still be present. Place the vial in a safe location where it cannot be accidentally accessed by children, pets, or other household members who might not be aware of the recall status. Second, contact your healthcare provider right away. This is the most critical step because the recall notice does not provide a direct consumer hotline for refunds or replacements. Your doctor or pharmacist needs to know that you were prescribed or possess Lot AC-017273 of NDC 71170-721-01, which expires on December 12, 2026. They can advise you on whether you need an alternative prescription to manage your condition without interruption and can help determine the safest way to handle the recalled product. In many cases, healthcare professionals will coordinate with the distributor, Apollo Care, LLC, located at 3801 Mojave Ct, Ste 102, Columbia, MO 65202, to arrange for the proper return or destruction of the unsafe inventory. Third, do not attempt to sell or give away the recalled vials. Since this is a nationwide distribution issue within the U.S., distributing the product further could expose others to the same health risks. If you are unsure how to dispose of the medication, ask your pharmacist for local drug take-back programs. These programs ensure that pharmaceuticals are destroyed in an environmentally safe and secure manner, preventing them from entering the waste stream where they could be misused. Finally, keep a record of all communications with your healthcare provider and any correspondence you initiate with Apollo Care, LLC. Document the lot number, expiration date, and the steps you have taken to remove the product from use. This documentation may be useful if you need to seek reimbursement for the cost of a replacement prescription or if you experience any adverse health effects that require medical follow-up. While the recall notice does not outline a specific consumer refund process, maintaining clear records ensures you have the necessary evidence to advocate for your health and financial interests during this process.Your refund, repair, or replacement options
When you encounter a product recall, the most immediate and practical question is often, "What happens next?" Specifically, how do I get my money back or receive a safe substitute? It is important to approach this with clarity and calmness, understanding that the remedy for this specific recall is not explicitly detailed in the current FDA report. While many recalls involve straightforward returns for refunds or exchanges, the absence of stated remedy terms here means you cannot assume a standard process applies. Instead, you must rely on the official channels provided by the responsible party, Apollo Care, LLC, to determine your specific options.
The recall notice identifies Apollo Care, LLC as the entity responsible for this action. Located at 3801 Mojave Ct, Ste 102, Columbia, MO 65202, they are the primary point of contact for any resolution. Because the remedy is not stated in the public record, your first step should be to reach out to them directly. Do not assume that a refund will be automatic or that a replacement vial will be shipped without instruction. Pharmaceutical recalls involving particulate matter require careful handling, and the manufacturer needs to guide you through the safe return of any unused or partially used vials to prevent further distribution or accidental use.
If you purchased this item from a pharmacy, healthcare provider, or distributor, do not attempt to resolve the issue solely with the retailer. While they may offer customer service support, the liability and responsibility for the remedy lie with Apollo Care, LLC. They will likely provide specific instructions on whether you should return the product for a credit, receive a replacement batch (if available and deemed safe), or simply dispose of it safely under their guidance. It is crucial to follow their exact directions to ensure that any financial compensation or product exchange is processed correctly and that the recalled units are removed from circulation.
Keep all documentation related to this purchase, including your receipt, the lot number (AC-017273), and the expiration date (12/12/2026). These details will be essential when communicating with Apollo Care, LLC. If you are unsure how to contact them, you can start by visiting their official website or calling the address listed in Columbia, MO. In some cases, the FDA may update the recall notice with more specific remedy information as the investigation progresses. Until then, patience and direct communication with the manufacturer are your best tools for securing a resolution.
- Contact Apollo Care, LLC directly at 3801 Mojave Ct, Ste 102, Columbia, MO 65202.
- Do not assume a standard refund policy applies; follow their specific instructions.
- Keep your lot number (AC-017273) and receipt handy for verification.
- If you purchased through a healthcare provider, inform them so they can assist in contacting the manufacturer.
What can happen if you ignore it
It is completely understandable to feel hesitant about discontinuing a prescribed medication, especially one that plays a significant role in your daily health management. You might be worried about the logistics of contacting your provider, the potential gap in treatment, or simply the inconvenience of switching products. However, when a pharmaceutical product is recalled due to the presence of particulate matter, ignoring that warning carries risks that extend far beyond mere inconvenience. The specific hazard identified in this recall involves foreign material—described as nylon/polyamide and silk/proteinaceous-type substances—floating within a sterile multi-dose vial of semaglutide. This is not a minor cosmetic flaw; it is a fundamental breach of sterility and purity that can lead to serious, potentially life-threatening complications if the medication is administered.
Semaglutide is delivered via subcutaneous injection, meaning the medication bypasses the body’s natural digestive filters and enters the tissue layer directly beneath the skin. When particulate matter is present in the solution, these microscopic or visible fragments are injected directly into your body along with the drug. The human body does not recognize nylon, polyamide, or silk proteins as harmless substances when they appear in unexpected places within the tissue. Instead, the immune system often reacts to these foreign invaders by triggering an inflammatory response. This can result in localized reactions at the injection site, such as severe pain, persistent swelling, redness, and the formation of granulomas. A granuloma is essentially a small area of inflammation that forms when the body tries to "wall off" something it cannot remove or digest. These lumps can be painful, unsightly, and difficult to resolve without medical intervention.
The risks become even more concerning if the particulate matter enters the bloodstream or if the foreign material serves as a nidus for infection. Even though the vial is labeled "sterile," the presence of organic proteins like silk can provide a substrate for bacterial growth, especially in a multi-dose vial that is punctured repeatedly. If bacteria colonize around these particles, it can lead to local infections or, in rare but severe cases, systemic infections such as sepsis. Furthermore, because semaglutide affects blood sugar levels and other metabolic processes, introducing an unpredictable variable like foreign particulate matter can complicate your overall health management. You might experience unexpected adverse reactions that make it difficult to determine whether they are side effects of the medication itself or complications from the contamination.
Ignoring this recall also means you are unknowingly exposing yourself to a known defect without any guarantee of safety. The FDA’s classification of this as a Class II recall indicates that while the situation may not be immediately fatal in every instance, it is serious enough to cause temporary health problems or pose a threat to life if the problem worsens. By continuing to use the recalled lot (AC-017273), you are taking an unnecessary risk with your physical well-being for no therapeutic benefit. The integrity of the medication has been compromised, and no amount of shaking or filtering can safely remove these particulates once they are suspended in the sterile solution. Prioritizing your safety by stopping use immediately is the only way to ensure that your treatment remains both effective and safe.